Pacbio is in it for the long run
The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
The heat is on for Oxford Nanopore
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
The UK bets on Nanopore and Nudge for rapid Covid-19 tests
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Antitrust watchdog plunges Illumina’s megamerger into darkness
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.